Translation of "Endothelial dysfunction" in German

The early phase of atherogenesis is characterized by a so-called endothelial dysfunction.

Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway.

Conclusions: The results of the present study indicate endothelial dysfunction in patients with glaucoma.

Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction.

Aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction, although the precise mechanism of action is not yet clearly defined.

The compounds of the formula I are therefore suitable as valuable therapeutics for illnesses in which cell proliferation is a primary or secondary cause, and can therefore be used as antiatherosclerotics, agents against diabetic late complications, carcinomatous disorders, fibrotic disorders such as pulmonary fibrosis, hepatic fibrosis or renal fibrosis, endothelial dysfunction, organ hypertrophies and hyperplasias, in particular in prostate hyperplasia or prostate hypertrophy.

With this protection of the vessels against the endothelial dysfunction syndrome, compounds of the formula I are valuable pharmaceuticals for the prevention and for the treatment of coronary vasospasms, atherogenesis and atherosclerosis, left-ventricular hypertrophy and dilated cardiomyopathy, and thrombotic disorders.

As a result, the formation of endothelial dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, myocardial infarct, strokes or erectile dysfunction occurs.

Illnesses and pathological conditions which are associated with a low cGMP level or in which an increase in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular disorders such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarcts, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.

Endothelial dysfunction is responsible for the clinical signs observed in the mother, ie, impairment of the hepatic endothelium contributing to onset of the HELLP (Hemolysis, Elevated Liver enzymes and Low Platelet count) syndrome, impairment of the cerebral endothelium inducing refractory neurological disorders, or even eclampsia.

According to current knowledge impaired trophoblast invasion into the maternal spiral arteries of the uterus leads to placental dysfunction and release of pathogenic factors, systemic inflammation, endothelial dysfunction and clinical apparent disease.

The focus will be on the role of atherogenic factors of adipose tissue and the impact of the endothelium’s regenerative capacity in the pathogenesis of endothelial dysfunction.

In the present study we tried to gain more insight into this question by comparing the flicker responses in different groups with well established endothelial dysfunction.

It has, however, been hypothesized that this phenomenon may be related to endothelial dysfunction, because the retinal flicker response has been shown to be nitric oxide dependent.

In the case of ED, pathogenetic treatment is aimed at eliminating endothelial dysfunction, which is the basis of any form of organic disorders of erectile function.

Objective: Disturbances of microcirculation in general as well as endothelial dysfunction are the fundamentals of a lot of general vascular diseases like arterial hypertension, coronary heart disease, diabetes mellitus and migraine.

Magnesium has been shown to beneficially impact insulin resistance, serum lipid profiles, inflammation, endothelial dysfunction, oxidative stress and platelet aggregability (79).

With this protection of vessels against the syndrome of endothelial dysfunction, NHE inhibitors are valuable pharmaceuticals for the prevention and treatment of coronary vasospasms, peripheral vascular diseases, especially intermittent claudicating, parthenogenesis and atherosclerosis, left-ventricular hypertrophy and dilated cardiomyopathy, and thrombotic disorders.

Under pathophysiological conditions, the adrenergic system may be activated, which can lead, for example, to hypertension, heart failure, increased platelet activation, endothelial dysfunction, atherosclerosis, angina pectoris, myocardial infarction, thromboses, peripheral circulatory disturbances, stroke and sexual dysfunction.

As a result, the development of endothelial dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, myocardial infarct, strokes or erectile dysfunction occurs.

Diseases and pathological conditions which are associated with a low cGMP level or in which an increase in the cGMP level is desired and for whose therapy and prophylaxis compounds of the formula I can be employed are, for example, cardiovascular conditions such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, stable and unstable angina pectoris, thromboses, restenoses, myocardial infarcts, strokes, cardiac insufficiency or pulmonary hypertension, or, for example, erectile dysfunction, bronchial asthma, chronic renal insufficiency and diabetes.